Drug therapy for psoriatic arthritis in adults: update of a 2007 report.
Donahue KE, Jonas DE, Hansen RA, Roubey R, Jonas B, Lux LJ, Gartlehner G, Harden E, Yuen A, Thieda P, Morgan LC, Crotty K, Van Noord M
Record ID 32013000776
English
Authors' objectives:
To compare the benefits and harms of corticosteroids and oral and biologic disease-modifying antirheumatic drugs (DMARDs) for adults with psoriatic arthritis (PsA).
Authors' recommendations:
Overall, the data are quite limited and the evidence is insufficient to draw firm conclusions on comparative efficacy, effectiveness, and harms of either oral or biologic DMARDs for PsA. This report's findings did not reveal any differences with current standard of care. Head-to-head (RCTs) are needed to establish the comparative efficacy and safety of different treatments with and without corticosteroids, oral DMARDs, and biologic DMARDs, to determine the best therapy to prevent or minimize debilitating joint damage and optimize quality of life for people with PsA.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.effectivehealthcare.ahrq.gov/ehc/products/464/1045/CER54_PsoriaticArthritisDrugTherapies_FinalReport_20120601.pdf
URL for additional information:
http://www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=1045
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Arthritis, Psoriatic
- Drug Therapy
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.